scholarly journals Review of Procedures for Investigation of Anaesthesia-Associated Anaphylaxis in Newcastle, Australia

2008 ◽  
Vol 36 (2) ◽  
pp. 201-207 ◽  
Author(s):  
O. Mcneill ◽  
R. K. kerridge ◽  
M. J. Boyle

The procedures, results and outcomes of investigation of 50 patients with clinical episodes of anaesthesia-associated anaphylaxis were retrospectively reviewed. Assessment was performed by measurement of serum tryptase and specific IgE and a combination of skin prick and intradermal skin testing. Testing was performed both for agents received during the anaesthetic and for agents the patient may encounter in future procedures. Twenty of 50 patients underwent a subsequent procedure after assessment. Sensitisation to neuromuscular blocking agents was identified in 18 patients (36%). Sensitisation to propofol (14 patients; 28%) and latex (four patients; 8%) was also frequently identified. No precise cause was identified in 11 cases (22%). Reactivity to more than one agent was identified in 14 patients (28%). Serum tryptase was measured within six hours of the episode in only 28 of the 50 cases. All the patients with elevated serum tryptase had clinically severe reactions. One patient initially found to be sensitised to propofol had another reaction during a second procedure, prompting further assessment where chlorhexidine reactivity was identified. Subsequent surgery in that patient and in 19 other patients where agents implicated in the testing were avoided, proceeded without incident. The results reaffirm that neuromuscular blocking agents are the most common cause of anaphylaxis during anaesthesia. The importance of serum tryptase measurement at the time of the acute episode needs to be emphasised. Investigation should include screening for chlorhexidine and latex in all patients, as exposure to both these agents is common and may be overlooked.

2001 ◽  
Vol 18 (Supplement 23) ◽  
pp. 104-105
Author(s):  
D. Laroche ◽  
M. C. Vergnaud ◽  
J. L. Guéant ◽  
C. Mouton ◽  
M. C. Laxenaire ◽  
...  

2018 ◽  
Vol 120 (6) ◽  
pp. 1437-1440 ◽  
Author(s):  
A.M. Chiriac ◽  
C. Tacquard ◽  
N.B. Fadhel ◽  
C. Pellerin ◽  
J.M. Malinovsky ◽  
...  

2021 ◽  
pp. 0310057X2096857
Author(s):  
Brian L Erstad ◽  
Jeffrey F Barletta

There is no consensus on which weight clinicians should use for weight-based dosing of neuromuscular blocking agents (NMBAs), as exemplified by differing or absent recommendations in clinical practice guidelines. The purpose of this paper is to review studies that evaluated various size descriptors for weight-based dosing of succinylcholine and non-depolarising NMBAs, and to provide recommendations for the descriptors of choice for the weight-based dosing of these agents in patients with obesity. All of the studies conducted to date involving depolarising and non-depolarising NMBAs in patients with obesity have assessed single doses or short-term infusions conducted in perioperative settings. Recognising that any final dosing regimen must take into account patient-specific considerations, the available evidence suggests that actual body weight is the size descriptor of choice for weight-based dosing of succinylcholine and that ideal body weight, or an adjusted (or lean) body weight, is the size descriptor of choice for weight-based dosing of non-depolarising NMBAs.


2009 ◽  
Vol 24 (1) ◽  
pp. 50-57 ◽  
Author(s):  
Cynthia A. Lien ◽  
Peter Savard ◽  
Matthew Belmont ◽  
Hiorshi Sunaga ◽  
John J. Savarese

Sign in / Sign up

Export Citation Format

Share Document